Inhibitory effects of evodiamine on human osteosarcoma cell proliferation and apoptosis

Abstract

Osteosarcoma is a primary malignancy of bone, which is characterized by the proliferation of malignant mesenchymal cells, particularly in children and adolescents. Evodiamine is extracted from a variety of traditional Chinese medicines, which has been reported to induce apoptosis in certain tumors, including cervical, prostate and breast cancer, however, its effect on oestosarcoma cells remains unclear. The aim of the present study was to investigate the effect of evodiamine on osteosarcoma cell proliferation and apoptosis, and explore the associated underlying molecular mechanism. A Cell Counting Kit 8 assay was performed to detect the effects of evodiamine on the proliferation of human osteosarcoma U2OS cells. Annexin V-fluorescein isothiocyanate/propidium iodide staining was performed to analyze the apoptotic rate of the cells. The effect of evodiamine on the protein expression levels of B-cell lymphoma-2 (Bcl-2), Bcl-2-associated X protein (Bax), caspase-3 and survivin were detected by performing western blot analysis. Evodiamine inhibited the growth of human osteosarcoma U2OS cells by inhibiting cell proliferation and inducing cell apoptosis. Western blotting demonstrated that evodiamine downregulated the expression of Bcl-2, caspase-3 and survivin, and upregulated the expression of Bax in human osteosarcoma cells. Evodiamine effectively inhibited proliferation and induced apoptosis of osteosarcoma cells in a dose-dependent manner via downregulation of Bcl-2, caspase-3 and survivin protein expression levels and upregulation of Bax protein expression levels.

Keywords: apoptosis; evodiamine; osteosarcoma cells; proliferation.

Figure 1

Proliferative inhibition effects of evodiamine on human osteosarcoma U2OS cells (^*P<0.05, vs. the control group).

Figure 2

Effect of evodiamine on the apoptosis of U2OS cells using flow cytometry. (A) Control group; (B) 0.5 μg/ml evodiamine; (C) 2.5 μg/ml evodiamine; and (D) 12.5 μg/ml evodiamine.

Figure 3

Protein expression levels of Bcl-2 and Bax following treatment with increasing concentrations of evodiamine for 12 h. 0, control group; 0.5, 0.5 μg/ml evodiamine; 2.5, 2.5 μg/ml evodiamine; 12.5, 12.5 μg/ml evodiamine.

Figure 4

Protein expression levels of caspase-3 following treatment with increasing concentrations of evodiamine for 12 h. 0, control group; 0.5, 0.5 μg/ml evodiamine; 2.5, 2.5 μg/ml evodiamine; 12.5, 12.5 μg/ml evodiamine.

Figure 5

Protein expression levels of survivin following treatment with increasing concentrations of evodiamine for 12 h. 0, control group; 0.5, 0.5 μg/ml evodiamine; 2.5, 2.5 μg/ml evodiamine; 12.5, 12.5 μg/ml evodiamine.